Morristown, NJ (USA), 14 February 2019 – Lonza is showcasing its portfolio of naturally derived, clean-label solutions and cutting-edge delivery systems at this year’s Natural Products Expo West in Anaheim, California. At booth 4005 Lonza’s Consumer Health & Nutrition team will show its latest science-backed innovations designed to meet holistic consumer health needs across human nutrition, pet nutrition and personal care.
At the show Lonza will launch new concepts for active nutrition, joint health and healthy aging, as well as promote its latest patent for Carniking® L-Carnitine for the pet nutrition market.
As the clean-label movement continues to grow, the demand for natural, plant-based and vegetarian and vegan products continues to increase across the global dietary supplements market. New U.S. consumer insights, commissioned by Lonza and conducted by the Natural Marketing Institute (NMI), found that 43% of supplement users believe that knowing the source of ingredients is very important when making a purchasing decision; and 38% also seek products that are derived from natural sources, up 59% over the last five years.
At the booth the team will present the latest addition to its range of clean-label food-colored capsules, the Vcaps® Plus Purple Carrot capsule. These innovative capsules comprise a shell made from only plant-based hypromellose and water and coloring from the extract of purple carrots. The Vcaps® Plus Purple Carrot capsule offers a solution to manufacturers and brand owners looking to add naturally sourced color to their vegetarian capsules without compromising on a clean label positioning. Product concepts at the booth will also feature Lonza’s scientifically backed ResistAid® proprietary ingredient for immune support. Extracted from North American Larch Trees using a steam-only process, ResistAid® ingredient (larch arabinogalactan) offers year-round immune benefits.
UC-II® and Dosage Form Solutions
Visitors to booth 4005 will have the opportunity to discover Lonza’s wider capabilities in supporting a holistic approach to health and well-being. These products include its patented UC-II® undenatured type II collagen, which is clinically proven to support joint health and mobility by improving joint comfort and flexibility. Also featured at the show will be Lonza’s innovative dosage-form solutions, including its DRcaps™ delayed release HPMC capsules, which are designed to protect dietary supplement ingredients, such as probiotics, from stomach acidity and moisture. Vegetarian and non-GMO certified, the capsules can also help mask taste and odor and reduce bad aftertaste without the addition of costly coatings.
Pet Nutrition Concepts
Lonza is also bringing new clean-label solutions to the pet nutrition market. The demand for natural and holistic products has gained traction in the pet nutrition space in recent years, with more and more pet owners mirroring their pet food purchases with their own dietary preferences.
Drawing on 30 years of experience and innovation in ingredients, Lonza was recently granted U.S. Patent 10,016,382 for its Carniking® L-Carnitine ingredient for active dogs and working animals. It is also expanding applications for its UC-II® ingredient in pet nutrition with a focus on supporting pet health and well-being.
For the first time, Lonza will also showcase naturally derived personal care innovations at the exhibition. These products include Digital Defense for Eyes and Skin, which combines ScreenLight® Block, a functional cutting-edge bioactive technology that uses natural extracts in a skincare formulation to protect against photo-aging from digital devices.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma & Biotech segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group LtdTel +41 61 316 8540
Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
 Natural Marketing Institute, 2018 Lonza SORD Report, published 2019.